Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology announced a non-compliance incident involving Mr. Cho, a non-executive director, whose spouse sold shares during a black-out period without prior notification. The company is taking steps to prevent future incidents by enhancing compliance training and awareness among its directors and staff.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It focuses on developing innovative oncology therapies and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 4,153,490
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.25B
Learn more about 9966 stock on TipRanks’ Stock Analysis page.